IL301783A - Preparations and methods for diagnosing cancer - Google Patents

Preparations and methods for diagnosing cancer

Info

Publication number
IL301783A
IL301783A IL301783A IL30178323A IL301783A IL 301783 A IL301783 A IL 301783A IL 301783 A IL301783 A IL 301783A IL 30178323 A IL30178323 A IL 30178323A IL 301783 A IL301783 A IL 301783A
Authority
IL
Israel
Prior art keywords
ganglioside
subject
sample
cancer
level
Prior art date
Application number
IL301783A
Other languages
English (en)
Hebrew (he)
Original Assignee
Aoa Dx
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aoa Dx filed Critical Aoa Dx
Publication of IL301783A publication Critical patent/IL301783A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G01N2405/10—Glycosphingolipids, e.g. cerebrosides, gangliosides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Peptides Or Proteins (AREA)
IL301783A 2020-10-05 2021-10-05 Preparations and methods for diagnosing cancer IL301783A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063087427P 2020-10-05 2020-10-05
PCT/US2021/053503 WO2022076364A1 (en) 2020-10-05 2021-10-05 Compositions and methods for cancer diagnosis

Publications (1)

Publication Number Publication Date
IL301783A true IL301783A (en) 2023-05-01

Family

ID=81126198

Family Applications (1)

Application Number Title Priority Date Filing Date
IL301783A IL301783A (en) 2020-10-05 2021-10-05 Preparations and methods for diagnosing cancer

Country Status (10)

Country Link
US (1) US20250277793A1 (https=)
EP (1) EP4225365A4 (https=)
JP (1) JP2023553247A (https=)
KR (1) KR20230155419A (https=)
CN (1) CN117120086A (https=)
AU (1) AU2021357695A1 (https=)
CA (1) CA3197304A1 (https=)
IL (1) IL301783A (https=)
MX (1) MX2023003771A (https=)
WO (1) WO2022076364A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315829A (en) * 2022-04-04 2024-11-01 Aoa Dx Mass spectrometry methods for cancer diagnosis
WO2025096441A1 (en) * 2023-10-30 2025-05-08 The Board Of Trustees Of The Leland Stanford Junior University Ganglioside gm2 as a target for cancer immunotherapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2329897A1 (en) * 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
ES2904533T3 (es) * 2013-12-06 2022-04-05 Aoa Dx Compuesto antigangliósido para dirigirlo contra el cáncer y generar anticuerpos
WO2017048823A1 (en) * 2015-09-18 2017-03-23 Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation Immunogenic glycopeptide compounds, pharmaceutical compositions and uses thereof
WO2018112669A1 (en) * 2016-12-23 2018-06-28 Realist Pharma, Inc. Ganglioside carbohydrate structures and uses thereof

Also Published As

Publication number Publication date
EP4225365A4 (en) 2024-11-13
EP4225365A1 (en) 2023-08-16
AU2021357695A1 (en) 2023-06-01
CN117120086A (zh) 2023-11-24
US20250277793A1 (en) 2025-09-04
KR20230155419A (ko) 2023-11-10
MX2023003771A (es) 2023-06-22
WO2022076364A1 (en) 2022-04-14
CA3197304A1 (en) 2022-04-14
JP2023553247A (ja) 2023-12-21

Similar Documents

Publication Publication Date Title
US11498963B2 (en) Anti-LILRB antibodies and their use in detecting and treating cancer
US20250108115A1 (en) Kir3dl3 as an hhla2 receptor, anti-hhla2 antibodies, and uses thereof
CN105209919B (zh) 治疗pd-1和pd-l1相关疾患的生物标志物和方法
JP2023040115A (ja) 葉酸受容体１の検出用の抗体及びアッセイ
US8067186B2 (en) Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
JP6564408B2 (ja) Ｓ１００ａ４抗体およびその治療上の使用
US20080213267A1 (en) Cytotoxicity mediation of cells evidencing surface expression of TROP-2
KR20190015408A (ko) 종양을 치료하는 방법에 사용하기 위한 항-pd-1 항체
JP6890581B2 (ja) Ｃｄ３７の検出のための抗体およびアッセイ
US20220144959A1 (en) Amhrii-binding compounds for preventing or treating cancers
JP2009531293A (ja) Ｃｄ５９表面発現の証拠となる、細胞における細胞毒性の媒介
CN101547936A (zh) 癌性疾病调节抗体
CN101553259A (zh) 显示cd63表面表达的细胞的细胞毒性介导
US20250277793A1 (en) Compositions and methods for cancer diagnosis
US9512223B2 (en) Methods for treatment of gastric cancer
KR20220103921A (ko) 암을 치료하기 위한 dkk-1 길항제의 용도
CA3208974A1 (en) Ctla4-binding proteins and methods of treating cancer
US20230416399A1 (en) Methods for treating cancer with anti-gd2/gd3 antibodies
TW202602493A (zh) 用於治療癌症的抗ｃｄ３６抗體
US9539348B2 (en) Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof